Clinical trials: Stage II Lung Cancer
Lung Cancer
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy…
- Trial name
- NCT00226590
- Testing
- Gemcitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
1. To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy. 2.
- Trial name
- NCT00984997
- Testing
- Surgery, Chest Irradiation, Cisplatin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Lung Cancer
Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer
Primary Objectives: The primary objectives of this study are as follows: To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of escalating ABT-751 in combination with fixed dose carboplatin in…
- Trial name
- NCT00735878
- Testing
- ABT-751 and Carboplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Konstantin Dragnev
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- PAINT (NCT02073968)
- Testing
- Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Albert Einstein College of Medicine
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
Lung Cancer
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00801385
- Testing
- erlotinib hydrochloride, sorafenib tosylate, DNA analysis
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Non Small Cell Lung Cancer
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Current studies confirmed that the immune perioperative treatment with combination chemotherapy curative effect and safety of resectable NSCLC, but its short-term curative effect and long-term survival benefit remains to be…
- Trial name
- NCT06467617
- Testing
- Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Beijing Chest Hospital, Capital Medical University
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00040768
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Carcinoma of Lung, Locally Advanced
Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC
This is a prospective, single-arm phase II clinical study enrolling patients with locally advanced unresectable non-small cell lung cancer.
- Trial name
- NCT07882940
- Testing
- Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Non Squamous Non Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
- Trial name
- Spruce (NCT01829113)
- Testing
- OGX-427
- Where
- 16 sites in United States
- Volunteers
- 155 people
- Sponsor
- SCRI Development Innovations, LLC
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.
- Trial name
- ICWIP (NCT02125240)
- Testing
- Icotinib
- Where
- 11 sites in China
- Volunteers
- 124 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Lung Cancer, Precancerous Condition
Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Polyphenon E, a substance found in green tea, may keep cancer from forming in current or former smokers with bronchial dysplasia.
- Conditions
- Lung Cancer, Precancerous Condition, Tobacco Use Disorder
- Trial name
- NCT00611650
- Testing
- defined green tea catechin extract
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- British Columbia Cancer Agency
Lung Cancer
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00407550
- Testing
- gemcitabine HCL, pemetrexed disodium
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Squamous Cell Lung Cancer
Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.
This is a prospective, single-arm, multi-center, phase Ⅱ trial to evaluate the efficacy and safety of Polymeric Micelles paclitaxel(pm-Pac), platinum (cisplatin/carboplatin) in combination with Ivonescimab as first-line treatment…
- Trial name
- NCT07009925
- Testing
- Ivonescimab 20mg/kg intravenous every 3 weeks
- Volunteers
- 38 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Small Cell Lung Cancer
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
- Trial name
- NCT00374140
- Testing
- RAD001 (everolimus)
- Where
- 19 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ahmad Tarhini
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05498389
- Testing
- EMB-01, Osimertinib
- Where
- 3 sites in United States, China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Non-small Cell Lung Cancer
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
This is a multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of pyrotinib maleate as a first-line treatment for HER2-mutated or amplified non-small cell lung cancer.
- Trial name
- NCT05751018
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking Union Medical College Hospital
Non Small Cell Lung Cancer
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
The purpose of this randomized phase II trial is to determine the clinical feasibility - in terms of patients without dose limiting toxicities or premature treatment withdrawal or death - of the combination of Cisplatin and…
- Trial name
- NCT00349089
- Testing
- Pemetrexed, Cisplatin, Vinorelbine
- Where
- 14 sites in Belgium, Germany and 1 more
- Volunteers
- 132 people
- Sponsor
- Thoraxklinik-Heidelberg gGmbH